Mastocytosis - an update.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Mastocytosis (MC) is a heterogeneous group of disorders characterized by clonal mast cell accumulation.
• A somatic activating mutation in the tyrosine kinase receptor Kit (D816V) is found in over 90% of adult MC patients.
• MC affects skin and bone marrow, with symptoms varying due to mediator release and organ dysfunction.

Purpose of the Study:

• To provide a comprehensive overview of mastocytosis, including its pathophysiology, clinical manifestations, diagnosis, and current treatment strategies.
• To highlight the heterogeneity of MC and its impact on patient outcomes.
• To discuss future directions in MC management and research.

Main Methods:

• Review of existing literature and clinical guidelines on mastocytosis.
• Analysis of diagnostic hallmarks, including skin and bone marrow biopsies and serum tryptase levels.
• Evaluation of current and emerging therapeutic approaches for MC.

Main Results:

• The D816V Kit mutation is prevalent in adult MC, while less common in children.
• Common symptoms include pruritus, wheals, flushing, and gastrointestinal issues.
• Pediatric MC often achieves spontaneous remission, whereas adult MC is typically chronic and can rarely progress to aggressive forms.
• Increased risk of anaphylaxis is a significant concern in MC patients.
• Current treatments include H1 antagonists, with IFN-alpha and cladribine showing partial response in aggressive types.

Conclusions:

• Mastocytosis management requires a multidisciplinary approach, considering the disease's heterogeneity.
• Curative treatment is not yet available, but improved care is expected with updated classifications and networks.
• Ongoing research into tyrosine kinase inhibitors offers potential for future systemic treatments.